GSK Sees Blockbuster Chronic Cough Opportunity With $2bn Bellus Buyout
Potential Best-In-Class Drug
GSK has unveiled another targeted acquisition – of Bellus – that it hopes will bolster its presence in specialist respiratory medicine.
You may also be interested in...
Hyfe is extending AI to acoustics and championing technology it claims can transform the approach to cough management, leading to improved diagnoses, better treatment and superior health outcomes. CMO Peter Small explained the rationale and how AI has inspired a significant leap forward.
The ongoing downturn is making early-stage biotech leaders work harder to gain funding – but new technology, business focus and better working practices could help them achieve success.
Increased disease awareness and the IRA should help boost the RSV prevention market for older adults, said GSK CEO Emma Walmsley, ahead of a US approval decision early next month, as the firm’s vaccines division helped push a strong Q1 performance. Other deals are also ‘in the hopper.’